![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Modulators Have Different Impact on Synaptic Transmission in the Thalamus and Hippocampus
Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, Illinois
Received September 21, 2004; accepted December 22, 2004.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors enhance synaptic responses and facilitate synaptic plasticity. Those studies focused mainly on hippocampal functions. However, AMPA receptors have regionally distinct subunit compositions and thus potencies and efficacies of modulators may vary across the brain. The present study compared the effects of CX546 [1-(1,4-benzodioxan-6-ylcarbonyl) piperidine], a benzamide-type modulator, on synaptic transmission in neurons of the reticular thalamic nucleus (RTN), which regulates the firing mode of relay cells in other thalamic nuclei, and on hippocampal CA1 pyramidal cells. CX546 greatly prolonged synaptic responses in CA1 pyramidal cells, but at the same concentration it had only weak modulatory effects in RTN neurons. Effects on miniature excitatory postsynaptic currents (EPSCs) were similar to those on EPSCs in both regions, suggesting that variations in neuronal morphology and transmitter release kinetics do not account for the differences. Relay cells in the ventrobasal thalamus also exhibited weak modulatory effects that were comparable with those in RTN neurons. Regionally different effects on response duration were also observed with CX516 [BDP-12, 1-(quinoxalin-6-ylcarbonyl)piperidine], a second benzamide drug. In contrast, 100 µM cyclothiazide produced comparable synaptic enhancements in hippocampus and RTN. The regional selectivity of benzamide drugs (ampakines) may be explained, at least in part, by a lower potency at thalamic AMPA receptors, perhaps due to the prevalence of the subunits GluR3 and 4. Although regional preferences of the ampakines were modest in their extent, they may be sufficient to be of relevance when considering future therapeutic applications of such compounds.
), to facilitate synaptic plasticity (Arai and Lynch, 1992; Arai et al., 1996a, 2004), and to improve many forms of memory in animals and humans (Granger et al., 1996; Ingvar et al., 1997; Hampson et al., 1998). Most studies on the consequences of AMPA receptor modulation have focused on hippocampal synapses and on hippocampal tasks such as memory encoding. However, with AMPA receptors being abundant throughout the brain, the range of functions potentially susceptible to such modulation may be much wider. Moreover, since AMPA receptors can assemble in virtually any combination from the four constituent subunits GluR1 to 4 and their alternative splice variants called flip and flop, cell types differ widely in the composition of these receptors. The effect of a given AMPA receptor modulator may thus potentially vary between brain regions for several reasons. First, the modulator may discriminate among subunits. Second, receptors vary in their kinetic properties, such as in the rates at which receptors desensitize in the presence of glutamate or deactivate after removal of glutamate. Thus, if a modulator changes a particular rate constant underlying these processes, its efficacy may be different across receptors, depending on the relative importance of that rate constant for response dynamics. For example, desensitization seems to make a significant contribution to response termination in some neuron types (Gardner et al., 2001) but not in others (Arai and Lynch, 1998; Lin et al., 2002), and drugs that modulate desensitization would accordingly be expected to have more prominent effects in the former. Last, integration of multiple synaptic events may be influenced differentially by modulators, depending on extrasynaptic factors such as dendritic morphology (for review, see Spruston et al., 1994) or frequency and synchrony of afferent activity (Diamond and Jahr, 1995).
The present study examined the effects of some prototypical modulators on synaptic responses in the thalamus and compared them with those in pyramidal cells of hippocampal area CA1. The thalamus was selected because synaptic events often have a faster time course and AMPA receptors have different subunit compositions, with GluR3 and 4 subunits being more prevalent than the GluR1 and 2 subunits that are abundant in the hippocampus (Mineff and Weinberg, 2000; for review, see Jones, 2002). Tests were conducted mainly in the reticular thalamic nucleus (RTN), an area that exerts a complex integrative control over thalamic function, with some additional tests in thalamic relay cells, which are involved in communicating sensory information to the cortex.
A further factor to be taken into consideration is that existing AMPA receptor modulators are heterogeneous in structure and in the way they modify receptor kinetics and synaptic processes (Johansen et al., 1995; Arai and Lynch, 1998; Arai et al., 2000, 2002, 2004). Regional preferences may accordingly be specific for a given subtype of drug. The main focus of this study was on CX546, a first generation benzamide drug (ampakine) of relatively low potency but with high efficacy for prolonging synaptic responses (Nagarajan et al., 2001; Arai et al., 2002). Additional tests were conducted with CX516, another benzamide drug that enhances response amplitudes more prominently than duration (Arai et al., 1996b, 2002) and that has been the drug most extensively examined in behavioral and clinical tests (Lynch, 2003). A third modulator was cyclothiazide, which is particularly effective in blocking receptor desensitization (Yamada and Tang, 1993). A preliminary report of this work was published in abstract form (Xia et al., 2002).
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Whole-Cell Recording. Whole-cell recordings were made from cells in the RTN and the ventrobasal (VB) thalamic nucleus and from hippocampal CA1 pyramidal cells. Neurons were visualized with an infrared microscope (BX50WI; Olympus, Tokyo, Japan) with differential interference contrast configuration, and whole-cell recording was established with borosilicate glass electrodes (5–10 MOhm) filled with the internal solution containing 130 mM CsF, 10 mM EGTA-K, 2 mM ATP-Na, 2 mM MgCl2, and 10 mM HEPES, pH 7.35 (270–285 mOsm). Synaptic responses in the RTN were evoked by a bipolar nichrome stimulation electrode positioned in the internal capsule. For recordings in the VB, the stimulation electrode was positioned adjacent to the recording cell. Synaptic transmission in the CA1 area was induced by activation of Schaffer commissural fibers (see details in Arai et al., 2002). Stimulation intensity was adjusted so as to obtain 30 to 50% of the maximum amplitude, and constant current stimulation was delivered every 15 s. In addition, a brief voltage jump of -10 mV for 60 ms was applied before every stimulation to monitor access resistance. Experiments with changes in access resistance of more than 30% were excluded from analysis. After establishing a stable baseline, the drug was introduced in the recording chamber. The time for solution exchange of the small-volume recording chamber was 3 min. Excitatory postsynaptic currents (EPSCs) were recorded with AxoPatch 200B and digitized at 10 kHz with Digidata1200B/pClamp 9. The holding potential was maintained at -70 mV, and all the experiments were carried out at room temperature (22–24°C).
Data analysis was carried out off-line. The decay phase of the response was fitted with a biexponential function. The quality of fitting was assessed from correlation statistics. Fast and slow decay time constants and the corresponding fractional amplitude contributions were compared before and in the presence of the drug. To obtain a weighted decay time constant, the fast and slow decay time constants were multiplied by their respective fractional amplitude and summed. In some experiments, spontaneous miniature excitatory postsynaptic currents (mEPSCs) were recorded from CA1 pyramidal cells and RTN neurons. Access resistance was monitored throughout the experiments. Spontaneous events were selected with a template event detection tool in pClamp 9 (Clements and Bekkers, 1997). Experiments with average rise times larger than 2.5 ms were excluded from final analysis. Decay time constants were calculated by fitting the response decay phase with a single exponential function.
Drugs. The AMPA receptor modulators CX546 and CX516 were provided by Dr. G. Rogers (Cortex Pharmaceuticals, Irvine, CA). All other agents, including cyclothiazide, were purchased from Sigma-Aldrich (St. Louis, MO). Stock solutions of AMPA receptor modulators were prepared in dimethyl sulfoxide and diluted at least 1000 times for every experiment. Stock solutions for D-AP5, 6-cyano-2,3-dihydroxy-7-nitroquinoxaline, and MK-801 were prepared in water or aqueous buffers.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Gentet and Ulrich, 2003). As a consequence, all subsequent experiments were carried out in the presence of 10 µM MK-801 and 50 µM D-AP5. The remaining current was abolished by 20 µM 6-cyano-2,3-dihydroxy-7-nitroquinoxaline and 40 µM GYKI 52466 (data not shown), indicating that the currents are mediated through AMPA receptors. As illustrated in Fig. 1A, AMPA receptor-mediated EPSCs in RTN had a faster time course than those at synapses between Schaffer commissural fibers and pyramidal cells in hippocampal area CA1. On average, the rise time (1.76 ± 0.13 ms) and half-width (6.2 ± 0.6 ms; n = 40) were about 2.5 times smaller than in the hippocampus (4.4 ± 0.5 and 17.3 ± 1.3 ms, respectively; n = 29) (also see Arai et al., 2004).
|
CX546 was shown previously to produce robust increases in AMPA receptor currents in patches excised from hippocampal pyramidal cells and from human embryonic kidney 293 cells expressing recombinant AMPA receptors (Arai et al., 2002). Kinetic analysis revealed that its main effect was to slow response deactivation up to 10-fold. The most prominent effect on synaptic transmission accordingly was to increase response duration, both in hippocampal slices (Arai et al., 2002, 2004) and primary cultures (Nagarajan et al., 2001). In agreement with these previous studies, CX546 at 400 µM greatly prolonged response duration at CA1 pyramidal cell synapses as indicated by a 168 ± 29% (n = 7) increase in response half-width, with comparably modest effect on amplitude (Fig. 1, A and B). By comparison, effects on RTN cells were remarkably weak at all concentrations tested (Fig. 1, A and B). Response half-width was increased by only 68 ± 16% (n = 8) at 400 µM, and even at 800 µM the increase was smaller (104 ± 18%; n = 9) than that obtained in the hippocampus with 400 µM drug. CX546 at 200 µM increased the amplitude by 40 ± 13% (n = 10) in the hippocampus but by only 5 ± 6% (n = 6) in RTN neurons; the increase over baseline in the hippocampus (p = 0.016; two-tailed) as well as the difference to the RTN (p = 0.029; one-tailed) were significant.
Closer inspection of the traces showed that response decay often is biphasic, before and after infusion of drug. According to biexponential curve fittings, the slow component accounted for about 20% of total amplitude in control responses of both brain regions (Fig. 1, C and D). The dominant fast component had a significantly shorter decay 
in RTN neurons (4.6 ± 0.8 ms) than in the hippocampus (10.2 ± 1.7 ms; p < 0.01), as expected from the comparisons of response half-width discussed above, but the slow decay components were not statistically different, although the time constant tended to be larger in the RTN. Drug effects on these measures of response wave form differed again between the two brain regions. In the hippocampus, CX546 significantly increased both the fast (1.4x) and the slow (2.1x) decay time constants, but the most prominent change was an increase in the contribution of the slow component from 23 to 69% of total response amplitude (Fig. 1D; p < 0.01) (also see Arai et al., 2004). The remaining fast component probably reflects in part the presence of receptors in which the drug sites were not or only partially occupied, owing to the fact that the drug concentration of 400 µM is not saturating. In the RTN, changes in response parameters were much smaller. The fast decay time constant increased 1.3 times (p < 0.05), but the time constant of the slow component seemed to be reduced (0.75x), and the contribution of the slow component to total response amplitude increased to merely 34 ± 5% (from 23% before drug). Differences in the latter values did not reach significance due to the variability inherent in such fittings. To quantify drug effects further, we determined for each experiment a weighted decay time constant and the total charge transfer. The values are summarized in Table 1, along with other response parameters and input resistance. In CA1 pyramidal cells, the weighted time constant increased by a factor of 4.3 ± 0.6 after infusion of 400 µM CX546, whereas RTN neurons exhibited virtually no change. Similarly, charge transfer increased 2.5 times in hippocampal neurons but only 1.2 times in the RTN. Thus, CX546 influences the duration of excitatory responses in RTN neurons to a lesser extent, regardless of the parameter used to express response duration. No significant effects were observed, however, on response rise time or amplitude, and no differences were evident in the input resistance (Table 1).
|
Effects of CX546 on Miniature Spontaneous EPSCs in the RTN and Hippocampus. As shown above, the time course of evoked responses in hippocampal pyramidal cells is considerably slower than in RTN neurons. The reasons are not yet fully understood. Differences in the subunit composition of AMPA receptors may play a role because RTN cells mainly contain GluR3 and 4 subunits (Golshani et al., 2001), which may have faster kinetics (Mosbacher et al., 1994; Sekiguchi et al., 1997). However, other factors may be of similar or greater importance, such as dendritic filtering and regional differences in transmitter release kinetics. It has also been suggested that asynchronous release of transmitter broadens the waveform of hippocampal EPSCs (Diamond and Jahr, 1995). It is thus conceivable that the seemingly more robust effects of CX546 in the hippocampus result from factors unrelated to AMPA receptors, such as an enhanced visibility of the drug effect due to cumulation of early and delayed response components. If this were the case then regional differences in drug effects should disappear when measuring mEPSCs. Drug effects on hippocampal mEPSCs in particular would be expected to become smaller and closer in magnitude to those seen in EPSCs from RTN neurons.
This was examined in the experiments shown in Fig. 2. Spontaneous miniature events were recorded under blockade of NMDA and GABAA receptors. In hippocampal recordings, the time course of the averaged spontaneous events varied considerably between cells, and only experiments in which a majority of events (>85%) had a rise time faster than 2.5 ms were chosen for analysis. The spontaneous events in these selected experiments showed a mean rise time of 1.6 ± 0.3 ms (n = 5), which is 2.8 times shorter than that of evoked EPSCs (Table 1); this rise time was comparable with the average value obtained in RTN neurons in both spontaneous (1.4 ± 0.3 ms; n = 10; Table 2) and evoked responses (1.4 ± 0.4 ms; Table 1). Fitting an exponential function to the decay phase of these spontaneous mEPSCs yielded mean decay time constants of 4.2 ± 0.9 ms for hippocampal responses and 4.1 ± 0.5 ms for RTN responses. Thus, time course and waveform of the spontaneous mEPSCs before drug was similar in both brain regions. Given that the time course of hippocampal mEPSCs is much faster than for evoked EPSCs, the miniature events probably originated from synapses close to the soma, which would minimize the influence of dendritic filtering.
|
|
The effects of 400 µM CX546 on spontaneous events are illustrated in Fig. 2 and summarized in Table 2. The time course of mEPSC recorded in the RTN remained similar to that before drug (Fig. 2, A and B), with little change in the rise time and with decay time constants being increased to only a modest degree (44 ± 14%; n = 10; Fig. 2D). In contrast, miniature events in hippocampal neurons were greatly prolonged. The decay time constant for these events was increased on average by a factor of 3.0 ± 0.7 to a value of 13 ± 4 ms (Fig. 2D). The difference in the changes of the decay time constant between hippocampus and RTN is significant at p = 0.037 (Table 2). In either region, the drug had no significant effect on the frequency of the events or on the mean amplitude (Fig. 2, C and D). The rise time was increased in the hippocampus (p < 0.05), but comparison of the averaged ratios in RTN versus hippocampus was not significant.
Together, the effects of CX546 on spontaneous mEPSCs are in quantitative agreement with the results from evoked EPSCs even though the time course of the control spontaneous event is about 2.8 times faster than that of evoked EPSCs. The larger effects of CX546 in the hippocampus are thus likely to reflect a genuine property of its synapses and their AMPA receptors.
Effects of CX546 on Excitatory Synaptic Transmission in Thalamocortical Neurons of the Ventrobasal Complex. Differences in drug effects may be the consequence of variations in subunit composition, including the relative prevalence of the splice variants flip and flop. AMPA receptors in hippocampal pyramidal cells from rats older than postnatal day 5 are mainly composed of GluR2 subunits in combination with GluR1 and 3 (Keinanen et al., 1990; Zhu et al., 2000). In contrast, receptors in the RTN and most other thalamic nuclei seem to consist mostly of GluR3 and 4 (Mineff and Weinberg, 2000; Ibrahim et al., 2000; Golshani et al., 2001; Jones 2002) with notable absence of GluR1 and 2, at least in the rodent thalamus (Liu et al., 2001). However, receptor composition varies to some extent also between thalamic nuclei. For instance, corticothalamic synapses in the RTN contain a 3 to 4 times higher amount of GluR4, but not GluR3, than those on thalamic relay cells in the VB, which has been suggested to correlate with the higher amplitude of unitary EPSCs seen in the former (Golshani et al., 2001). We therefore also examined the effects of CX546 on relay cells in the VB. Excitatory synaptic transmission was recorded from these cells in response to activation of the fibers within the VB. The time course of the EPSCs was considerably slower than that typically seen in RTN neurons; the rise time of 4.2 ± 0.7 ms and the half-width of 18 ± 3 ms (n = 11) were in fact similar to the values obtained in the hippocampus (Fig. 3, A and B). However, the effect of 400 µM CX546 was comparable in magnitude to that in RTN cells, with a 54 ± 18% increase in half-width (n = 7); the difference to the effect obtained at hippocampal synapses is significant at p < 0.01 (Fig. 3, C and D). Also, the contribution of the slow decay component to total response amplitude increased to only about 30% in the presence of the drug, as it had been the case in RTN neurons (data not shown). These findings suggest that CX546 may have low effectiveness at synapses throughout the thalamus, regardless whether EPSCs recorded in those neurons have fast or slow response waveforms. It also tentatively suggests that it is the general lack of GluR1 and 2 subunits, which accounts for the low effectiveness in the thalamus, rather than local variations in densities of GluR3 and 4.
|
Effects of CX516 and Cyclothiazide on Excitatory Synaptic Transmission in the RTN and Hippocampus. To test whether AMPA receptor modulators in general have weaker effects in RTN neurons, two other drugs were examined that were previously found to be effective in the hippocampus. Cyclothiazide potentiates both amplitude and duration in hippocampal whole-cell recordings (Rammes et al., 1994; Lin et al., 2002; Arai et al., 2004), and CX516 (BDP-12) showed a preference for enhancing response amplitude more than duration, a preference that is opposite to that of CX546 (Arai et al., 1996b, 2002, 2004). In RTN neurons, the onset of drug action and the time to achieve plateau effects were generally the same as in hippocampal neurons. As shown in Fig. 4, cyclothiazide was highly effective in enhancing both amplitude and half-width of responses in the RTN, and the magnitude of its effects were similar to those in the hippocampus. This rules out the possibility that drug access to synapses on RTN neurons is generally impaired. Results with 1 mM CX516 differed somewhat for amplitude and half-width measures. The amplitude increase in the RTN was sizable (116 ± 16%; n = 7), although it tended to be smaller than in the hippocampus. On the other hand, the drug had virtually no effect on half-width in the RTN but prolonged responses significantly in the hippocampus (by 111 ± 38%). These results suggest that benzamide-type drugs (CX546 and CX516) may have generally weaker effects on response duration at RTN synapses.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Arai et al., 2002). It should be noted, however, that the magnitude of the drug effect could not be examined at truly saturating drug concentrations and hence the possibility of additional differences in drug efficacy cannot be ruled out.
A potentially confounding factor has been that basal AMPA receptor-mediated responses differ in their time course between RTN and hippocampus, with rise and decay times being 2 to 3 times slower in the latter. Importantly, however, miniature events are similarly fast in both structures. This suggests that the kinetic properties of their AMPA receptors are not very different and that EPSC waveforms in the hippocampus are instead more strongly influenced by factors such as asynchrony in transmitter release (Diamond and Jahr, 1995), ineffective removal of glutamate (Lawrence et al., 2003), and dendritic filtering. Our data indicate, however, that the higher effectiveness of CX546 in the hippocampus is not the result of such nonsynaptic factors. Spontaneous miniature EPSCs in the hippocampus exhibited a 3-fold widening in the presence of the drug, which is comparable in magnitude with the effect on evoked EPSCs, whereas miniature EPSCs in the RTN again exhibited only modest changes. Since mEPSCs represent single release events and mostly originate from synapses close to the cell body, one can conclude that the drug-induced large changes in the waveforms of hippocampal responses are not artifactually caused by poor space clamp efficiency or by asynchronous transmitter release and instead reflect genuine receptor properties. These conclusions are further supported by the observation that the changes produced by CX546 in ventrobasal thalamic neurons were weak like in RTN neurons, in spite of the fact that their EPSCs had a slow time course like hippocampal neurons.
If the observed differences in drug effects reflect true receptor properties, then they presumably result from variations in the subunit composition of the AMPA receptor or from secondary receptor modifications. It may be significant in this context that neurons throughout the thalamus contain mainly GluR3 and 4 subunits (Spreafico et al., 1994), whereas receptors in hippocampal pyramidal cells contain GluR1–3 with GluR2 being dominant. Leever et al. (2003) indeed observed that CX546 had a preference for GluR2 over GluR3 and 4 in oocyte recordings, which would in broadest terms agree with our observations that drug effectiveness was lower in both RTN and ventrobasal nucleus. However, regional differences in splice variants may also have contributed since benzamides often exhibit a mild preference for flop variants (Johansen et al., 1995; Partin et al., 1996; Arai et al., 2000), and flop variants are prominent in area CA1 (Sommer et al., 1990) even at a relatively early age (Arai and Lynch, 1996). Unfortunately, data about splice variant prevalence in the thalamus and elsewhere are still sparse. The original in situ hybridization study by Monyer et al. (1991) on flip-flop variant distributions in the brain indicated a particularly strong GluR3 flip signal in the RTN region of postnatal day 8 animals, but beyond this it does not allow for quantitative comparisons with other subunits and splice variants. Nonetheless, it may be instructive that CX546 exhibited a 3-fold lower potency in modulating [3H]AMPA binding to GluR3-flip receptors than to GluR3 flop and GluR2 receptors (Table 3; Arai et al., 2000). Thus, the lower susceptibility of the thalamus for CX546 perhaps resulted from a combination of having more GluR3 than GluR2 subunits and being enriched in the flip splice variant of this subunit.
|
Drug potencies could also be influenced in ways that are not readily apparent from tests with recombinantly expressed homomeric receptors, for example, due to secondary receptor modifications such as phosphorylation or specific receptor interactions with local synaptic proteins. For example, the negative AMPA receptor modulator GYKI 53655 exhibited up to 10-fold lower potencies for modulating recombinantly expressed subunits than for native receptors (Partin and Mayer, 1996), and the latter showed positive modulatory effects in addition to the negative modulatory action typically seen with recombinant receptors (Arai, 2001). No disparities of such magnitude have been reported for positive AMPA receptor modulators, but there is evidence for general differences in kinetic properties between recombinant and native AMPA receptors, for example, in their binding affinities (Suzuki et al., 2003), and thus modulatory drug effects on native synaptic receptors could also differ in ways that cannot be predicted from subunit characteristics alone.
CX516 consistently enhanced response amplitude more than duration, as in previous reports (Arai et al., 1996a, 2002). At the concentration used here, the amplitude increase in RTN neurons was smaller than in the hippocampus, but the difference was modest. However, effects on response half-width differed greatly with essentially no change in RTN neurons versus a doubling in the hippocampus. This can again be potentially explained by a lower potency of this drug at thalamic synapses. CX516 in hippocampal field recordings had a lower EC50 for enhancing amplitude (180 µM; Arai et al., 1996b) than for enhancing half-width (>1 mM). Thus, the concentration of 1 mM may have been sufficiently high to cause a substantial increase in the amplitude of RTN responses, even with reduced potency, but it may have been too low to significantly enhance response duration if the EC50 for response duration was increased accordingly. Cyclothiazide produced comparable increases in amplitude and half-width in both brain regions. It is possible, however, that the concentration of cyclothiazide used here was closer to saturation and thus regional differences in potency may have been less evident (also see Arai and Lynch, 1996).
Because of the growing interest in their therapeutic potential, many AMPA receptor modulators have been screened for subunit preferences with the expectation that such preferences could be used to direct drug action to particular brain regions. The general observation has been that most modulators exhibit only modest discrimination, with subunit affinities usually differing by factors far smaller than 10. Nonetheless, the present study has documented that the effects of such drugs on synaptic transmission can differ severalfold between brain regions, and this may be sufficiently distinct to be of importance when considering therapeutic applications. Our results would tentatively suggest, then, that Ampakine modulators such as CX546 are more suitable to enhance hippocampal functions, which include memory encoding, than to modulate thalamic functions, which include wakefulness and vigilance. We can at this point not rule out, however, that changes in AMPA receptor subunit expression later in development, such as the progressive expression of GluR4 subunit in the thalamus (Spreafico et al., 1994), or potential changes in the balance between flip and flop variants, would alter again the effectiveness of these drugs and perhaps reduce the degree of discrimination between hippocampus and thalamus. Such predictions will not be feasible unless it is clarified whether the regional selectivities reported here indeed result from differences in subunit expression patterns or from secondary receptor modifications. In addition, more precise information is needed about the molecular makeup of AMPA receptors across brain regions and developmental stages, both in animals and humans.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: AMPA, -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; RTN, reticular thalamic nucleus; CX546, 1-(1,4-benzodioxan-6-ylcarbonyl) piperidine; CX516, 1-(quinoxalin-6-ylcarbonyl)piperidine; ACSF, artificial cerebrospinal fluid; NMDA, N-methyl-D-aspartate; MK-801, dizocilpine maleate; VB, ventrobasal nucleus of the thalamus; EPSC, excitatory postsynaptic current; mEPSC, miniature excitatory postsynaptic current; D-AP5, D-2-amino-5-phosphonovaleric acid; GYKI 52466, 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine.
Address correspondence to: Dr. A. C. Arai, Department of Pharmacology, Southern Illinois University, School of Medicine, 801 N. Rutledge St., P.O. Box 19629, Springfield, IL 62794-9629. E-mail: aarai{at}siumed.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Arai A, Guidotti A, Costa E, and Lynch G (1996a) Effects of IDRA 21, a cognitive enhancer, on synaptic transmission and long-term potentiation in hippocampal slices. Neuroreport 7: 2211-2215.[Medline]
Arai A, Kessler M, Rogers G, and Lynch G (1996b) Effects of a memory enhancing drug on AMPA receptor currents and synaptic transmission in hippocampus. J Pharmacol Exp Ther 278: 627-638.
Arai A and Lynch G (1992) Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation. Brain Res 598: 173-184.[CrossRef][Medline]
Arai A and Lynch G (1996) Response to repetitive stimulation of AMPA receptors in patches excised from fields CA1 and CA3 of the hippocampus. Brain Res 716: 202-206.[CrossRef][Medline]
Arai A and Lynch G (1998) The waveform of synaptic transmission at hippocampal synapses is not determined by AMPA receptor desensitization. Brain Res 799: 230-234.[CrossRef][Medline]
Arai AC (2001) GYKI 52466 has positive modulatory effects on AMPA receptors. Brain Res 892: 396-400.[CrossRef][Medline]
Arai AC, Kessler M, Rogers G, and Lynch G (2000) Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466. Mol Pharmacol 58: 802-813.
Arai AC, Xia Y-F, Rogers G, Lynch G, and Kessler M (2002) Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action. Mol Pharmacol 303: 1075-1085.
Arai AC, Xia Y-F, and Suzuki E (2004) Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. Neuroscience 123: 1011-1024.[CrossRef][Medline]
Baumbarger P, Muhlhauser M, Yang CR, and Nisenbaum ES (2001) LY392098, a novel AMPA receptor potentiator: electrophysiological studies in prefrontal cortical neurons. Neuropharmacology 40: 992-1002.[CrossRef][Medline]
Clements JD and Bekkers JM (1997) Detection of spontaneous synaptic events with an optimally selected template. Biophys J 73: 220-229.[Medline]
Diamond JS and Jahr CE (1995) Asynchronous release of synaptic vesicles determines the time course of the AMPA receptor-mediated EPSC. Neuron 15: 1097-1107.[CrossRef][Medline]
Gardner SM, Trussell LO, and Oertel D (2001) Correlation of AMPA receptor subunit composition with synaptic input in the mammalian cochlear nuclei. J Neurosci 21: 7428-7437.
Gentet LJ and Ulrich D (2003) Strong, reliable and precise synaptic connections between thalamic relay cells and neurons of the nucleus reticularis in juvenile rats. J Physiol (Lond) 546: 801-811.
Golshani P, Liu XB, and Jones EG (2001) Differences in quantal amplitude reflect GluR4-subunit number at corticothalamic synapses on two populations of thalamic neurons. Proc Nat Acad Sci USA 98: 4172-4177.
Granger R, Deadwyler S, Davis M, Moskovitz B, Kessler M, Rogers G, and Lynch G (1996) Facilitation of glutamate receptors reverses an age-associated memory impairment in rats. Synapse 22: 332-337.[CrossRef][Medline]
Hampson RE, Rogers G, Lynch G, and Deadwyler SA (1998) Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 18: 2748-2763.
Ibrahim HM, Healy DJ, Hogg AJ Jr, and Meador-Woodruff JH (2000) Nucleus-specific expression of ionotropic glutamate receptor subunit mRNAs and binding sites in primate thalamus. Mol Brain Res 79: 1-17.[Medline]
Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers GA, Schehr RS, and Lynch G (1997) Enhancement by an ampakine of memory encoding in humans. Exp Neurol 146: 553-559.[CrossRef][Medline]
Johansen TH, Chaudhary A, and Verdoorn TA (1995) Interactions among GYKI-52466, cyclothiazide and aniracetam at recombinant AMPA and kainate receptors. Mol Pharmacol 48: 946-955.[Abstract]
Jones EG (2002) Thalamic circuitry and thalamocortical synchrony. Phil Trans R Soc Lond B Biol Sci 357: 1659-1673.
Keinanen K, Wisden W, Sommer B, Werner P, Herb A, Verdoorn TA, Sakmann B, and Seeburg PH (1990) A family of AMPA-selective glutamate receptors. Science (Wash DC) 249: 556-560.
Lawrence JJ, Brenowitz S, and Trussell LO (2003) The mechanism of action of aniracetam at synaptic -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: indirect and direct effects on desensitization. Mol Pharmacol 64: 269-278.
Leever JD, Clark S, Weeks AM, and Partin KM (2003) Identification of a site in GluR1 and GluR2 that is important for modulation of deactivation and desensitization. Mol Pharmacol 64: 5-10.
Lin B, Colgin LL, Brucher FA, Arai AC, and Lynch G (2002) Interactions between recording technique and AMPA receptor modulators. Brain Res 955: 164-173.[CrossRef][Medline]
Liu X-B, Bolea S, Golshani P, and Jones EG (2001) Differentiation of corticothalamic and thalamocortical collateral synapses on mouse reticular nucleus neurons by EPSC amplitude and AMPA receptor subunit composition. Thalamus Relat Syst 1: 15-29.
Lynch G (2003) AMPA receptor modulators as cognitive enhancers. Curr Opin Pharmacol 4: 4-11.[CrossRef]
Mineff EM and Weinberg RJ (2000) Differential synaptic distribution of AMPA receptor subunits in the ventral posterior and reticular thalamic nuclei of the rat. Neuroscience 101: 969-982.[CrossRef][Medline]
Monyer H, Seeburg PH, and Wisden W (1991) Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. Neuron 6: 799-810.[CrossRef][Medline]
Mosbacher J, Schoepfer R, Monyer H, Burnashev N, Seeburg P, and Ruppersberg JP (1994) A molecular determinant for submillisecond desensitization in glutamate receptors. Science (Wash DC) 266: 1059-1062.
Nagarajan N, Quast C, Boxall AR, Shahid M, and Rosenmund C (2001) Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. Neuropharmacology 41: 650-663.[CrossRef][Medline]
Partin KM, Fleck MW, and Mayer ML (1996) AMPA receptor flip/flop mutants affecting deactivation, desensitization and modulation by cyclothiazide, aniracetam and thiocyanate. J Neurosci 16: 6634-6647.
Partin KM and Mayer ML (1996) Negative allosteric modulation of wild-type and mutant AMPA receptors by GYKI 53655. Mol Pharmacol 49: 142-148.[Abstract]
Rammes G, Parsons C, Muller W, and Swandulla D (1994) Modulation of fast excitatory synaptic transmission by cyclothiazide and GYKI 52466 in the rat hippocampus. Neurosci Lett 175: 21-24.[CrossRef][Medline]
Sekiguchi M, Fleck MW, Mayer ML, Takeo J, Chiba Y, Yamashita S, and Wada K (1997) A novel allosteric potentiator of AMPA receptors: 4-2-(phenylsulfonylamino)ethylthio-2,6-difluoro-phenoxyacetamide. J Neurosci 17: 5760-5771.
Sommer B, Keinanen K, Verdoorn TA, Wisden W, Burnashev N, Herb A, Kohler M, Takagi T, Sakmann B, and Seeburg PH (1990) Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science (Wash DC) 249: 1580-1585.
Spreafico R, Frassoni C, Arcelli P, Battaglia G, Wenthold RJ, and De Biasi S (1994) Distribution of AMPA selective glutamate receptors in the thalamus of adult rats and during postnatal development. A light and ultrastructural immunocytochemical study. Dev Brain Res 82: 231-244.[CrossRef][Medline]
Spruston N, Jaffe DB, and Johnston D (1994) Dendritic attenuation of synaptic potentials and currents: the role of passive membrane properties. Trends Neurosci 17: 161-166.[CrossRef][Medline]
Suzuki E, Kessler M, and Arai AC (2003) Correlation between physiological affinity constants and binding affinities of recombinant homomeric AMPA receptors. Soc Neurosci Abstr 29: 359.6.
Warren JR and Jones EG (1997) Maturation of neuronal form and function in a mouse thalamocortical circuit. J Neurosci 17: 277-295.
Xia YF, Kessler M, and Arai AC (2002) Differential effect of AMPA receptor modulators on synaptic transmission in the thalamus and hippocampus. Soc Neurosci Abstr 28: 540.5.
Yamada KA and Tang C-M (1993) Benzothiadiazides inhibit rapid glutamate receptor desensitization and enhance glutamatergic synaptic currents. J Neurosci 13: 3904-3915.[Abstract]
Zhu JJ, Esteban JA, Hayashi Y, and Malinow R (2000) Postnatal synaptic potentiation: delivery of GluR4-containing AMPA receptors by spontaneous activity. Nat Neurosci 3: 1098-1106.[CrossRef][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
